摘要
Since type 2 diabetes mellitus (T2DM) is a risk factor for Alzheimer's disease (AD) and both have the same pathogenesis (e.g., insulin resistance), drugs used to treat T2DM have been gradually found to reduce the progression of AD in AD models. Of these drugs, glucagon-like peptide 1 receptor (GLP-1R) agonists are more effective and have fewer side effects. GLP-1R agonists have reducing neuroinflammation and oxidative stress, neurotrophic effects, decreasing A beta deposition and tau hyperphosphorylation in AD models, which may be a potential drug for the treatment of AD. However, this needs to be verified by further clinical trials. This study aims to summarize the current information on the mechanisms and effects of GLP-1R agonists in AD.
学科与关键词
- Alzheimer's disease, a metabolic disorder: Clinical advances and basic model studies (Review)Zhou, Shanhu; Tu, Limin; Chen, Wei; Yan, Gangli; Guo, Hongmei; Wang, Xinhua; Hu, Qian; Liu, Huiqing*; Li, Fengguang*Experimental and Therapeutic Medicine, 2024, 27(2): 63.
- The Impact of Glucagon-Like Peptide 1 Receptor Agonists on Bone Metabolism and Its Possible Mechanisms in Osteoporosis TreatmentXie, Baocheng; Chen, Shichun; Xu, Yongxiang; Han, Weichao; Hu, Runkai; Chen, Minyi; Zhang, Yusheng*; Ding, Shaobo*Frontiers in Pharmacology, 2021, 12: 697442.被引 19
- The Multifunctional Anti-inflammatory Drugs Used in the Therapy of Alzheimer's DiseaseShi, S.; Wang, Z.; Qiao, Z.*Current Medicinal Chemistry, 2013, 20(20): 2583-2588.被引 15
